by Mark Curtis | Feb 23, 2015
. Welcome to your deal review for the month of January. There was a mixed bag of news last month, which included financing activity, industry partnerships and research collaborations. The cell therapy tools industry was front and centre as NeoStem and Invetech struck...
by Stacey Johnson | Feb 20, 2015
. If you haven’t heard the name Janet Rossant, my guess is that you aren’t part of the stem cell community or you spend a little too much time in the lab. Dr. Rossant is Chief of Research at the Hospital for Sick Children in Toronto, Canada and she leads the new...
by Mark Curtis | Feb 19, 2015
. Welcome to your Update from the Clinic for the month of January. Pluristem and OncoMed reported preliminary efficacy data from early-stage trials, while the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) granted a number of Orphan Drug...
by James Smith | Jan 26, 2015
With contributions from David Brindley . Cell-based treatments are being developed and marketed for a variety of indications: from rare orphan diseases like graft versus host disease (GvHD), to blockbuster conditions like diabetes and cardiovascular disease that...
by Mark Curtis | Jan 7, 2015
. Welcome to your deal review for the month of December. Juno Therapeutics made its leap into the public realm with the largest biotech initial public offering (IPO) in 2014. bluebird Bio announced pricing of a common offering to raise over $200M. Read on to find out...
by Mark Curtis | Dec 23, 2014
. Welcome to your Update from the Clinic for the month of November. NeoStem announced initial positive data from its Phase 2 study in acute myocardial infarction. Neuralstem’s human neural stem cells are shown to have long-term viability following transplant, while...
Comments